THOMAS L MARTIN

Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology CLIVE, IA NPI 1417908922

General Payments — all program years on this page

$1,782.62

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 134
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $305.23 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $305.2319

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Celgene Corporation $88.206
ABBVIE INC. $78.955
Takeda Pharmaceuticals U.S.A., Inc. $29.901
Phathom Pharmaceuticals, Inc. $28.252
UCB, Inc. $18.471
Organon LLC $17.621
PFIZER INC. $15.771
Gilead Sciences, Inc. $14.451
Lilly USA, LLC $13.621

By program year

Program yearAmountRecords
2018 $239.0027
2019 $257.8327
2020 $53.494
2021 $194.7011
2022 $407.1728
2023 $325.2018
2024 $305.2319

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1101115146 Celgene Corporation $15.43 01/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101115148 Celgene Corporation $13.32 05/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101115150 Celgene Corporation $15.64 07/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101115154 Celgene Corporation $13.17 09/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101115156 Celgene Corporation $13.74 09/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101115158 Celgene Corporation $16.90 10/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104974459 ABBVIE INC. $17.45 05/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104974461 ABBVIE INC. $16.71 06/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104974463 ABBVIE INC. $13.34 06/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104974465 ABBVIE INC. $14.32 07/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104974467 ABBVIE INC. $17.13 11/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131181377 PFIZER INC. $15.77 02/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133640638 Gilead Sciences, Inc. $14.45 08/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135449794 Lilly USA, LLC $13.62 08/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136244730 Organon Llc $17.62 04/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137630332 Takeda Pharmaceuticals U.S.A., Inc. $29.90 09/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143267521 UCB, Inc. $18.47 06/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151093663 Phathom Pharmaceuticals, Inc. $14.79 03/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151093665 Phathom Pharmaceuticals, Inc. $13.46 10/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.